Reimagining the future of Huntington’s disease
SOPHIA Huntington’s Disease Community Advocate
Press Releases
Subscribe to receive breaking news alerts about uniQure.
Subscribe-
-
uniQure Announces $150 Million Proposed Public Offering
-
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy